Director, Corporate Communications

Needham, MA (Hybrid)

$215K/yr – $240K/yrDirector/Executive10+ years expFull time

Posted 5 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own investor relations storytelling and executive communications that translate R&D milestones into a clear, differentiated corporate narrative across investors, media, and analysts while coordinating with the CEO, CFO, and cross-functional leaders.

  • IR/Executive Messaging: Develop and review materials for investor meetings, earnings calls, and industry events to align with company strategy and milestones.
  • Thought Leadership & Visibility: Increase executive presence via conferences, panels, and awards, backed by external communications plans and content.
  • Cross-Functional Collaboration: Partner with Corporate Affairs, Legal, Finance, Medical Affairs, Clinical Development, and R&D to ensure messaging accuracy and approvals across external materials.

Job Description

Responsibilities

  • Corporate, investor, executive and R&D communications
  • Increase awareness and visibility of Xenon’s emerging leadership in epilepsy and neuropsychiatry, growing pain portfolio, and emergence as a leading biopharma company soon to be a fully integration commercial organization
  • Lead development of corporate messaging and materials, including press releases, Q&As, corporate presentations, executive talking points, social media content, etc., in collaboration with Corporate Affairs, Brand Communications, the CFO, CEO, Medical Affairs, Clinical Development, Commercial, Legal, Regulatory, and other parts of the organization.
  • Build strategies around and execute programming for corporate stakeholders including investors, media, investigators, partners and policymakers/influencers.
  • Collaborate with the CFO, CEO, Corporate Affairs and Executive Leadership team to craft clear, consistent messaging around company strategy, pipeline, and milestones.
  • Lead development of briefing materials for management in preparation for investor meetings.
  • Manage the company’s participation in banking conferences, non-deal roadshows, and analyst/investor days through effective project management and relationship management strategies.
  • Lead the discussions and development of IR/Industry conference presentations, panels/Q&As, PRs, through collaboration with subject matter experts and leaders across the organization, as well as materials reviews.
  • Drive and support preparation of earnings calls, press releases, and SEC filings (10-K, 10-Q, 8-K) in coordination with Finance and Legal.
  • Maintain Xenon’s Investor Relations website, including ongoing maintenance and content updates as needed in collaboration with the website vendor.

Requirements

  • Bachelor’s degree or equivalent, ideally with a specialization in Finance, Business, Life Sciences, or Communications; master’s or advanced degree preferred.
  • Biotech or pharma industry experience is required; 10+ years of investor relations experience, ideally in the healthcare sector.
  • Strong communications expertise, including written, verbal, presentation, interpersonal skills, with the ability to translate and simplify complex scientific information and clinical data for research analysts and investors.
  • Proven track record of developing corporate and investor communication messaging and materials.
  • Experience developing executive level communications and engaging directly with senior management.
  • Superior interpersonal and external and internal customer relationship management skills.
  • Comprehensive understanding of the biotech industry, drug development and commercialization.
  • Issues management experience with a track record of successfully planning for and publicly addressing high profile business topics with key external stakeholders.
  • Experience developing analysis of sell side research and sell side and buy side relationships encouraged.
  • Highly organized, with attention to detail, adherence to deadlines, and ability to work under pressure with multiple, shifting priorities.

Preferred

  • Master’s or advanced degree preferred.
  • Experience developing analysis of sell side research and sell side and buy side relationships encouraged.

Benefits

  • Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions.
  • Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown.
  • Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.
Xenon Pharmaceuticals logo

Xenon Pharmaceuticals

4.7 Glassdoor

Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Our lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). We are also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. We have offices in Vancouver, British Columbia, and Boston, Massachusetts.

Founded in 1996
Burnaby, British Columbia, CAN
393 employees (24 in marketing)
94% recommend to a friend

Traffic Signals

Monthly Visitors
19.4K
Monthly Google Ads Budget
$8.3K
Traffic Source Mix
Search
55.4%
Direct
33.7%
Referral
5.7%
Social
3.7%
Paid
1.4%

Headcount Trend

Current headcount: ~393

Marketing Team

Marketing Team Size
24 (6% of company)
Marketing Roles Posted (Last 30 Days)
2

Funding

Total Funding
$1.8B
Last Raise
$550.7M
Post IPO Equity, 6 days ago

Funding History

  • Mar 2026
    Post IPO Equity • $550.7M
  • Nov 2023
    Post IPO Equity • $300M
  • Jun 2022
    Post IPO Equity • $287.5M

Recent News